Anti-Viral Drug Therapy Market Definition

The anti-viral drug therapy market consists of sales of branded and generic anti-viral drugs and related services by entities (organizations, sole traders and partnerships) that manufacture branded or generic anti-viral drugs to treat microbial infections. The anti-viral drug therapy industry includes establishments that manufacture anti-viral drugs, which are used to treat diseases or illnesses caused by viral infections. Examples of antiviral drugs include idoxuridine, famiciclovir, cidofovir, amantadine, zanamivir, tenofovir, adefovir and ribavirin. Viruses are infective agents comprising of a core of nucleic acids, either RNA or DNA, and are surrounded by a layer of protein. These are not living organisms, and can reproduce only inside a living cell. Anti-viral drugs decrease the ability of viruses to reproduce. These drugs enter the cells infected with virus, and interfere with the ability of the virus to bind to the cell, and stimulate the immune system of the host.

Influenza diagnostic is the test used to diagnose influenza including viral culture, serology, rapid antigen testing, reverse transcription-polymerase chain reaction (RT-PCR), immunofluorescence assays, and rapid molecular assays. Influenza, commonly known as flu, is a contagious illness caused by the influenza virus. Three varieties of this virus affect people: type A, type B, and type C. Common symptoms include fever, sore throat, cough, body ache, fatigue, and headache. The market consists of revenues generated by establishments conducting diagnostics tests for influenza virus detection. The main traditional diagnostic test types of influenza diagnostics are rapid influenza diagnostic tests (RIDT), viral culture, DFA, serological assays and others. Rapid influenza diagnostic tests (RIDTs) are immunoassays that can detect the presence of influenza A and B viral nucleoprotein antigens in respiratory specimens and provide a qualitative result (positive vs. negative). The various molecular diagnostic tests include Reverse Transcription Polymerase Chain Reaction (RT-PCR), Isothermal Nucleic Acid Amplification Tests (INAAT), loop mediated isothermal based amplification assays, transcription mediated isothermal based amplification assays, transcription mediated isothermal based amplification assays, other isothermal nucleic acid amplification tests and are used by hospitals and clinical laboratories, diagnostic reference laboratories, academic/research institutes, other end users. The influenza diagnostic market research report is one of a series of new reports from The Business Research Company that provides influenza diagnostic market statistics, including influenza diagnostic industry global market size, regional shares, competitors with a influenza diagnostic market share, detailed influenza diagnostic market segments, market trends and opportunities, and any further data you may need to thrive in the influenza diagnostic industry. This influenza diagnostic market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global influenza diagnostic market size will grow from $2.42 billion in 2022 to $2.59 billion in 2023 at a compound annual growth rate (CAGR) of 6.9%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global influenza diagnostic market size is expected to grow to $3.37 billion in 2027 at a CAGR of 6.8%. The major factor driving the market is increasing funding for research on influenza diagnostics. Addressing the public health impact of influenza disease requires a proper understanding of the virus and its effect on individuals and populations. Therefore, it is important to accelerate the pace of scientific research progress that can have the greatest public health impact. Many public and private health organizations, researchers, health professionals, biopharmaceutical companies have maximized the spending for research funds or grants to reduce the risk of the emergence of pandemic influenza. For instance,in April 2021, the National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health, funded $24 million to help five Centres of Excellence for Influenza Research and Response (CEIRR), including the one at St. Jude Children's Research Hospital. More than $8.9 million of the first year's funding for St. Jude's research provided by the federal contract was to understand better, forecast, track, and treat developing influenza and other viruses. The variability in sensitivity and specificity among the influenza diagnostic tests is restraining the growth of the market. In most rapid flu tests, there are difficulties in identifying patients with influenza. The sensitivity of rapid flu tests ranges from 10-80% across various patient populations. Most diagnostic tests show an increase in the rate of false-negative results during low influenza virus activity, which often leads to an incorrect diagnosis. Thus, the variability in sensitivity and specificity is restraining the growth of the influenza diagnostic market. Rapid influenza diagnostic tests (RIDTs) are increasingly being implemented in influenza diagnostics. RIDTs are immunoassays which can identify the presence of influenza A and B viral nucleoprotein antigens in respiratory specimens and display the result in a qualitative way (positive vs. negative). It can yield results in a clinically relevant time frame of less than approximately 15 minutes and diagnose patients, who are present with influenza-like illness, mainly if it is performed within the first four days of the onset of symptoms. The rising popularity of RIDT is due to the benefits such as simple to use and rapid diagnosis. In February 2021, Thermo Fisher Scientific Inc., a US-based company specialising in clinical development, acquired Mesa Biotech, Inc. for an undisclosed amount. Through this acquisition, Thermo Fisher will increase manufacturing volume, achieve cost efficiencies, and deliver much-needed diagnostics to market faster and at a larger scale. Mesa Biotech, Inc. is a US-based infectious disease diagnostic company. Major players in the influenza diagnostics market are F. Hoffmann-La Roche Ltd., Quidel Corporation, ?h?rm? F??h?r, Abbott Laboratories, Hologic, Becton Dickinson and Company, DiaSorin S.p.A., Luminex Corporation, Meridian Bioscience Inc. and GenMark Diagnostics. North America was the largest region in the influenza diagnostics market in 2022. Western Europe was the second largest region in the global influenza diagnostics market. The regions covered in the global influenza diagnostic market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the influenza diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The influenza diagnostic market includes revenue earned by test kit and reagents, and other products. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global influenza diagnostic market is segmented - 1) By Traditional diagnostic tests: Rapid influenza diagnostic tests (RIDT), Viral Culture, DFA, Serological assays, Other Traditional diagnostic tests 2) By Molecular diagnostic tests: Reverse Transcription Polymerase Chain Reaction (RT-PCR), Isothermal Nucleic Acid Amplification Tests (INAAT), Loop Mediated Isothermal Based Amplification Assays, Transcription Mediated Isothermal Based Amplification Assays, Transcription Mediated Isothermal Based Amplification Assays, Other Isothermal Nucleic Acid Amplification Tests, Other Molecular Diagnostic Tests 3) By End User: Hospitals & Clinical Laboratories, Diagnostic Reference Laboratories, Academic/Research Institutes, Other End Users

COVID-19 drug-associated APIs refer to the active pharmaceutical components that are employed in the production of COVID-19 medications. Chemicals called "active pharmaceutical components" serve as the foundation for pharmaceutical drugs and medicines and are responsible for pharmacological activity in the human body. The main classes of drugs in COVID-19 drug-associated APIs are antimalarials, bronchodilators, antibiotics, antivirals, and others. Antimalarial drugs, or simply "antimalarials," are antiparasitic chemical agents that can be used to cure or prevent malaria. They are generally organically sourced. The different types of drugs include generic, branded, and involve various modes of business such as captive API and merchant API. The COVID-19 drug-associated APIs market research report is one of a series of new reports from The Business Research Company that provides COVID-19 drug-associated APIs market statistics, including global market size, regional shares, competitors with a COVID-19 drug-associated APIs market share, detailed COVID-19 drug-associated APIs market segments, market trends and opportunities, and any further data you may need to thrive in the COVID-19 drug-associated APIs industry. This COVID-19 drug-associated APIs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global covid19 drug associated apis market grew from $5.99 billion in 2022 to $6.37 billion in 2023 at a compound annual growth rate (CAGR) of 6.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The covid19 drug associated apis market is expected to grow from $8.02 billion in 2027 at a CAGR of 5.9%. High demand for some antiretrovirals, antimalarials, sedatives, bronchodilators and other respiratory drugs drives the demand for the active pharmaceutical ingredients (APIs) used in the production of COVID-19 drugs. Active pharmaceutical ingredients (APIs) are the biologically active component used in manufacturing pharmaceutical drugs. Remdesivir and Favipiravir are two common antiviral medications used currently for the treatment of COVID-19 patients. Remdesivir is a medication approved for emergency use in the USA and Japan for the treatment of COVID-19 patients. Remdesivir received emergency use authorization (EUA) from the FDA on May 1, 2020, based on its preliminary data showing a faster time to recovery in hospitalised patients with several diseases. Favipiravir, which is used to treat influenza in Japan, has also shown a positive effect on COVID patients. As COVID-19 is a respiratory ailment, the demand for bronchodilators spiked significantly. Therefore, the increasing demand for antivirals, antimalarials, and bronchodilators is projected to boost the demand for the COVID-19-associated drug APIs market over the forecast period. The disruptions caused by the COVID-19 outbreak in the supply chain of medical products limited the growth of the COVID-19 drug-associated APIs market in the past few months. The source for APIs plays a crucial part in the strategic plan to combat the COVID-19 pandemic. The majority of APIs for generic drug manufacturing across the globe are sourced from India, with nearly 30% of generic APIs used in the USA. The restrictions imposed on the export of pharmaceutical products owing to COVID-19 supply chain disruptions restricted market growth. For instance, India imposed an export ban on 26 pharmaceutical products and medical devices in March 2020. The ban was imposed due to API and other bulk drug supply chain disruptions caused by restrictive measures such as lockdowns and factory closures in many countries around the world to ensure disease containment.Thus, shortages caused by disruptions in supply chains and restrictions imposed on the export of pharma products impacted the growth of the COVID-19 drug-associated APIs market over the last few months. Key players operating in the pharmaceutical industry that manufactures COVID-19 drug-associated APIs are focusing on strategies such as plant capacity or production capacity expansion to meet the increasing demand due to the rising number of coronavirus cases across the globe. For instance, in March 2020, Alembic Pharmaceuticals Ltd announced that the company is ramping up the production for the company’s production for azithromycin to 20 tonnes per month. Likewise, In April 2020, FUJIFILM Corporation announced the expansion of its manufacturing capacity and increase in the production of influenza antiviral Avigan Tablet (Favipiravir) by nearly 2.5 times by the end of July. Avigan is currently undergoing clinical trials testing its safety and efficacy for the treatment of COVID-19 patients. In February 2020, Dr. Reddy Labs announced the acquisition of the branded generics business of Wockhardt for an amount of $242 million (INR 1,850 crore). The acquisition is expected to scale up the former company’s presence in home markets including India, Nepal, Sri Lanka, Bhutan, and the Maldives. The Wockhardt business consists of a product portfolio of 62 brands in multiple therapy fields such as dermatology, neurology, respiratory, VMS, pain, gastroenterology, and vaccine. Wockhardt Ltd. was founded in 1999 and is a global biotechnology and pharmaceutical company based in Mumbai, India. Major players in the COVID-19 drug-associated APIs market are Dr. Reddy's Laboratories, Lianyungang Guike Pharmaceutical, Alembic Pharmaceutical, Wockhardt Ltd., Sandoz Srl, Lupin Limited, Aurobindo Pharma Ltd., Shanghai Shyndec Pharmaceutical (Haimen) Co. Ltd., and Yatai Pharma. North America is the largest region in the COVID-19 drug-associated APIs market in 2022. Middle East is expected to be the fastest growing region in the global COVID-19 drug associated apis market during the forecast period. The regions covered in the global COVID-19 drug-associated APIs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the COVID-19 drug-associated APIs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The COVID-19 drug associated APIs market consists of sales of acetaminophen (Tylenol) and ibuprofen (Motrin, Advil). Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organisations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global COVID-19 drug associated apis market is segmented - 1) By Drug Class: Antimalarials, Bronchodilators, Antibiotics, Antivirals, Other Drug Class 2) By Synthesis Type: Synthetic, Biotech 3) By Business Mode: Captive API, Merchant API

Anti-viral drug therapy refers to drugs that are used for the treatment of viral infections, such as human immunodeficiency virus (HIV), hepatitis, influenza, and novel coronavirus. Antiviral drugs do not kill their target pathogens; instead, they inhibit the development of those viruses. The anti-viral drug establishments are primarily engaged in the manufacturing of DNA polymerase inhibitors, reverse transcriptase inhibitors, protease inhibitors, neuraminidase inhibitors, and others. The main types of anti-viral drug therapy are branded and generic. The various drug classes involved are DNA polymerase inhibitors, reverse transcriptase inhibitors, protease inhibitors, neuraminidase inhibitors, and others that are used for HIV, hepatitis, herpes, influenza, and others. Reverse-transcriptase inhibitors (RTIs) are a type of antiretroviral medication used to treat HIV infection or AIDS, as well as hepatitis B in some cases. The anti-viral drug therapy market research report is one of a series of new reports from The Business Research Company that provides anti-viral drug therapy market statistics, including anti-viral drug therapy industry global market size, regional shares, competitors with an anti-viral drug therapy market share, detailed anti-viral drug therapy market segments, market trends and opportunities, and any further data you may need to thrive in the anti-viral drug therapy industry. This anti-viral drug therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global antivirals market size will grow from $97.14 billion in 2022 to $107.84 billion in 2023 at a compound annual growth rate (CAGR) of 11.0%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global antivirals market size is expected to grow to $156.99 billion in 2027 at a CAGR of 9.8%. The demand for anti-viral drugs is anticipated to grow at a rapid pace due to the novel coronavirus outbreak. As there are no vaccines and potential treatments for COVID-19, companies are trying to repurpose existing drugs in the fight against the novel coronavirus. The use of certain existing anti-viral drugs for the COVID-19 treatment is contributing to the growth of the anti-viral drugs market. However, if any of these drugs under trial show further promising results in treating the coronavirus infection, the anti-viral market will see further growth. Increasing public-private funding for life science research globally is expected to drive the growth of the anti-viral drug therapy market. Currently, there are no drugs or vaccines approved for the treatment of COVID-19 disease, however, there are several vaccines and drugs in the pipeline, that are yet to be approved or launched. Governments around the world announced new grant funds for researchers in vaccines, treatment, and diagnostics. In March 2020, the Canadian government announced $214.6 million for coronavirus research. Wellcome and the Gates Foundation announced they are joining forces with the credit card company MasterCard in a $125 million push to speed up the development of drugs for treating COVID-19 infections. Hence increasing public-private funding for life science research will enhance the research and development which drive the growth of the COVID-19 anti-viral drug therapy market. The emergence of alternative therapies such as naturopathy and homeopathy for the treatment of viral infections is negatively affecting the market. The development of COVID-19 anti-viral drugs involves high R&D costs. The development of COVID-19 anti-viral drugs involves high operating costs and requires a greater capital investment. Due to the high R&D costs involved in drug development, there is a growth in the demand for alternative medicines such as naturopathy and homeopathy. Saikosaponins (A, B2, C, and D), which are naturally occurring triterpene glycosides isolated from medicinal plants such as Bupleurum spp., Heteromorpha spp., and Scrophulariascorodonia, exert antiviral activity against HCV-22E9. Saikosaponins inhibit viral attachment and penetration stages. The marketed drugs would be priced much higher than the actual manufacturing costs. Hence using these naturopathy and homeopathy medicines can restrain the market growth. Companies in the anti-viral drug therapy market are continuously innovating through technological advancements to develop drugs to treat different viral infections. Biopharmaceutical companies are developing vaccines for the treatment of novel coronavirus. Technological advances in the pharmaceutical sector include the development of nucleic acid vaccines that are DNA- and RNA-based, and which enable the human body to produce vaccine antigens. In March 2020, Applied DNA Sciences’ subsidiary LineaRx and Takis Biotech formed a joint venture to develop a linear DNA vaccine as a treatment for coronavirus. The JV will use Polymerase Chain Reaction (PCR)-based DNA manufacturing technology to develop the vaccine. Such initiatives and activities are projected to support market growth to a significant extent. In February 2020, GeoVax, a US-based pharmaceutical company, and BravoVax, a China-based pharmaceutical company, announced plans to develop a coronavirus cure in the form of a vaccine based on the former’s MVA-VLP vaccine platform. BravoVax will be responsible for testing and manufacturing the vaccine as well as coordinating with the public health and regulatory authorities in China. GeoVax’s Modified Vaccinia Ankara platform enables enhanced expression and stable transgenes during the manufacturing process. Combined with the immunogenicity of Virus-Like Particles (VLPs), the technology enables the production of vaccines. The collaboration between these two companies is to develop a coronavirus vaccine. Major players in the anti-viral drug therapy market are AbbVie Inc., Bristol-Myers-Squibb, Cipla, F. Hoffmann-La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline, Johnson & Johnson, Merck & Co., Inc., Dr. Reddy’s Laboratories Ltd., AstraZeneca PLC., Aurobindo Pharma, Abbott Laboratories, Schering-Plough Corporation, Pfizer Inc., Sanofi, Sanofi, Regeneron Pharmaceuticals, Inc., Inovio Pharmaceuticals, Inc., Novavax, Inc., and BioCryst Pharmaceuticals, Inc. North America was the largest region in the anti-viral drug therapy market in 2022. The Middle East is expected to be the fastest-growing region in the global antivirals market during the forecast period. The regions covered in the global anti-viral drug therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the anti-viral drug therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA. The anti-viral drug therapy market consists of sales of amantadine and rimantadine. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global antivirals market is segmented - 1) By Drug Class: DNA Polymerase Inhibitors, Reverse Transcriptase Inhibitors, Protease Inhibitors, Neuraminidase Inhibitors, Other Drug Classes 2) By Application: HIV, Hepatitis, Herpes, Influenza, and Other Applications 3) By Type: Branded, Generic

The hospital-acquired infection testing kits are tools used to check the infections people get while in a healthcare facility. Hospital-acquired infections testing kits are used to check the infections associated with pathogens such as vancomycin-resistant enterococci (VRE), methicillin-resistant staphylococcus aureus (MRSA), multi-resistant gram-negative bacilli, norovirus, and Clostridium difficile. The main products of hospital-acquired infection testing kits are instruments, reagents, and consumables. The hospital-acquired infections testing kit instruments involve the various instruments that are required for hospital-acquired infections testing to aid scientists in growing new cells in the culture media for drug development, tissue culture, engineering, gene therapy, vaccine production, and toxicity testing. Pathogens tested using hospital-acquired infections testing kits include viral, bacterial, and fungal pathogens using sterilization, chemical, and radiation methods of treatment to test for pneumonia infection, urinary tract infection, bloodstream infection, surgical site infection, MRSA infection, and others.The various applications include drug-resistance testing and disease testing. The hospital-acquired infections testing kits market research report is one of a series of new reports from The Business Research Company that provides hospital-acquired infections testing kits market statistics, including hospital-acquired infections testing kits industry global market size, regional shares, competitors with a hospital-acquired infections testing kits market share, detailed hospital-acquired infections testing kits market segments, market trends and opportunities, and any further data you may need to thrive in the hospital-acquired infections testing kits industry. This hospital-acquired infections testing kits market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global hospital acquired infections testing kits market grew from $1.27 billion in 2022 to $1.4 billion in 2023 at a compound annual growth rate (CAGR) of 10.5%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The hospital acquired infections testing kits market is expected to grow from $2 billion in 2027 at a CAGR of 9.4%. The hospital-acquired infections (HAIs) are on the rise, affecting both the inpatients and outpatients. Hospital-acquired infections or nosocomial infections are diseases that are acquired in hospitals and medical clinics. For example, according to the findings by the Center for Disease Control and Prevention, around 1.7 million people in the USA acquire hospital-acquired infections caused while being admitted for other health issues and more than 98,000 (around 5%) patients die due to these infections. The increasing incidence of hospital-acquired infections leads to an increase in the demand for hospital-acquired infections testing kits. Most of the underdeveloped and developing nations lack proper health insurance that covers essential health services. According to a report by the World Bank and the World Health Organization, more than 50% of the world’s population cannot avail of essential health services due to expensive healthcare services that push them to poverty. For instance, 800 million people spend more than 10% of their household budgets on health expenses for themselves, a sick child, or other family members, and for almost 100 million people these expenses are high enough to push them into extreme poverty. This lack of financially affordable healthcare hinders the market growth for diagnostic services including hospital-acquired infection testing. The diagnostic tests involved in diagnosing HAIs such as flow cytometry, mass spectrometry, near-infrared spectroscopy, and nucleic acid-based technologies are advancing in technologies, providing more accurate data. There has been a significant advancement in mass spectrometers, which quantifies known materials, and identifies unknown compounds within a sample. For instance, SCIEX’s X500 QTOF solves the challenge of contamination and is a compact device that does not compromise on resolution and accuracy. It gives results sooner and allows the operator to make data-driven decisions sooner. The hospital-acquired infections testing kits are regulated by government agencies such as US FDA (Food and Drug Administration) in the USA, and the European Medicines Agency/Committee in European Region. The regulatory body lays down a set of guidelines pertaining to the safety, efficiency, and efficacy of the instruments that form part of the hospital-acquired infection testing kits market. The manufacturers and service providers must comply with the CBER Regulations that have been published in the first chapter of Title 21 of CFR. Part 600 of CFR 21 primarily focuses on the established standards like sample retention conditions, temperature to be maintained during shipment, sterilisation of equipment, and the role and duties of the inspector to inspect the laboratories. The regulation also allows the manufacturer to report any kind of deviation of their product from their intended purpose. CBER comes under the FDA (Food and Drug Administration). Also, the Code of Federal Regulations, Title 21, Part 866, states regulations pertaining to immunology and microbiology devices. These devices are used to identify infections caused by bacteria and various viruses. Major players in the hospital-acquired infections testing kits market are Becton, Dickinson and Company, Abott Laboratories, Cepheid, F. Hoffmann-La Roche Ltd., Hologic, Roche, Bayer AG, Cantel Medical Corporation, and Meridian Bioscience. North America was the largest region in the hospital-acquired infections testing kits market in 2022. Western Europe was the second largest region in the global hospital-acquired infections testing kits market. The regions covered in the global hospital-acquired infections testing kits market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the hospital-acquired infections testing kits market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The hospital-acquired infections testing kits market consist of sales of testing kits and devices. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organisations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products. The global hospital acquired infections testing kits market is segmented - 1) By Product: Instrument & Reagents, Consumables 2) By Test Type: Pneumonia Infection, Urinary Tract Infection, Blood Stream Associated Infection, Surgical Site Infection, MRSA Infection, Other Test Types 3) By Application: Drug-resistance Testing, Disease Testing 4) By Pathogen Type: Viral, Bacterial, Fungal 5) By Method of Treatment: Sterilization, Chemical, Radiation

The anti-infective drugs market consists of sales of anti-infective drugs and related services by entities (organizations, sole traders and partnerships) that produce anti-infective drugs to treat microbial infections. This industry includes establishments that produce antibiotics to treat bacterial infections, anti-viral drugs to treat viral infections, anti-fungal drugs to treat fungal infections, anti- helminthic drugs to kill internal parasites and antiprotozoal agents.

Liposomal drug delivery devices are microscopic colloidal spheres that are used to deliver drug molecules to the site of action. The main types of liposomal drug delivery devices are liposomal doxorubicin, liposomal paclitaxel, liposomal amphotericin B, and others. Liposomal doxorubicin is a kind of chemotherapy drug known as anthracycline wrapped up in a liposome. It slows or stops the increase of cancer cells by blocking an enzyme called topoisomerase. The applications included are fungal diseases, cancer therapy, pain management, viral vaccines, and photodynamic therapy that are used in hospitals, diagnostic centers, ambulatory surgery centers/clinics, and others. The liposomal drug delivery devices market research report is one of a series of new reports from The Business Research Company that provides liposomal drug delivery devices market statistics, including liposomal drug delivery devices industry global market size, regional shares, competitors with a liposomal drug delivery devices market share, detailed liposomal drug delivery devices market segments, market trends and opportunities, and any further data you may need to thrive in the liposomal drug delivery devices industry. This liposomal drug delivery devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global liposomal drug delivery devices market grew from $4.1 billion in 2022 to $4.5 billion in 2023 at a compound annual growth rate (CAGR) of 9.7%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The liposomal drug delivery devices market is expected to grow from $6.72 billion in 2027 at a CAGR of 10.6%. The rise in the number of cancer cases across the globe is likely to contribute to the growth of the liposomal drug delivery devices market during the forecast period. Liposomal drug delivery systems are used as targeted therapy for cancer treatment in radiation therapy, chemotherapy, and surgical resection. According to the American Cancer Society, there were 1.9million new cases and 0.6 million cancer deaths in 2021 in the USA. The four most common types of cancer worldwide are lung, prostate, bowel, and female breast cancer, accounting for 43% of all the new cancer cases. Therefore, the rise in cancer incidence rate globally is anticipated to boost the demand for the liposomal drug delivery devices market over the forthcoming years. The high cost of liposomal drug delivery devices is expected to limit the growth of the market during the forecast period. The high cost of devices makes liposomal treatment more expensive and unaffordable for patients, thereby hindering the growth of the market. For instance, according to the Journal of Biotechnology & Biomaterials, lipid/liposomal drug delivery systems are expensive to produce attributing to their high production cost. The high cost of products results from the high cost associated with the raw materials used in lipid excipients and the requirement of expensive equipment to increase manufacturing. Furthermore, according to the ScienceDirect Journal, liposomal drug delivery is the most expensive treatment for topical disorders such as psoriasis, atopic dermatitis, and skin cancer. Several big companies are undertaking various strategic initiatives such as collaborations and new product development, which is likely to become a major trend in the liposomal drug delivery devices market. Various companies are coming together to develop liposomal drug delivery systems to expand their product portfolio and operations worldwide. For instance, in 2021, MindMed is an Israeli creative drug development company, announced the execution of a Memorandum of Understanding regarding the introduction of an exclusive collaborative development program to optimize the supply of particular psychedelic drug candidates, leveraging Nextage's proprietary Brain Targeting Liposome System (BTLS) supply technology, for which it has a license. In March 2020, FUJIFILM Corporation announced its decision to offer contract services of process development and manufacturing of liposome formulations to its partners seeking drug delivery formulations that are designed to deliver the therapeutic to the affected sites. In July 2020, Croda International, PLC., a UK-based specialty chemicals company, acquired Avanti Polar Lipids, Inc. for $260 million. The acquisition is expected to expand life sciences products, cGMP production capabilities, and pharmaceutical services for biotechnology, life science, and expand customers for Croda International. Avanti Polar Lipids Inc. is a USA-based company that specializes in lipid-based drug delivery technology for next-generation pharmaceuticals. Major players in the liposomal drug delivery devices market are Fudan-Zhangjiang, Pacira, Johnson and Johnson, Gilead Sciences, Novartis, Luye Pharma, CSPC, Ipsen (Onivyde), Teva Pharmaceutical, and Sigma-Tau Group. North America was the largest region in the liposomal drug delivery devices market in 2022. Asia-Pacific was the second-largest region in the global liposomal drug delivery devices market report. The regions covered in the global liposomal drug delivery devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the liposomal drug delivery devices market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The liposomal drug delivery devices market consists of sales of instruments such as liposomal doxorubicin, liposomal paclitaxel, liposomal amphotericin B, and others. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global liposomal drug delivery devices market is segmented - 1) By Type: Liposomal Doxorubicin, Liposomal Paclitaxel, Liposomal Amphotericin B, Other Types 2) By Application: Fungal Diseases, Cancer Therapy, Pain Management, Viral Vaccines, Photodynamic Therapy 3) By End User: Hospitals, Diagnostic Centers, Ambulatory Surgery Centers/Clinics, Other End Users

Cancer vaccines refer to cancer-treatment vaccinations and medications that aid the body in illness prevention and cancer treatment. They have the power to teach the immune system to recognise and eliminate dangerous microbes and cells. The two main types of cancer vaccines are preventive cancer vaccines and therapeutic cancer vaccines. Therapeutic vaccinations aid in the recognition of a virus or malignant cell by the immune system. The different types of cancers include prostate, cervical, colorectal, throat, and others, and involve various technologies such as dendritic cells (DC) cancer vaccines, recombinant cancer vaccines, antigen/adjuvant cancer vaccines, whole cell cancer vaccines, viral vectors, and DNA cancer vaccines. The several sectors include cancer treatment centres and research institutes. The cancer vaccines market research report is one of a series of new reports from The Business Research Company that provide cancer vaccines market statistics, such as cancer vaccines industry global market size, regional shares, competitors with a cancer vaccines market share, detailed cancer vaccines market segments, market trends and opportunities, and any other information you may require to thrive in the cancer vaccines industry. This cancer vaccines market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global cancer vaccines market grew from $5.29 billion in 2022 to $6.2 billion in 2023 at a compound annual growth rate (CAGR) of 17.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The cancer vaccines market is expected to grow from $10.66 billion in 2027 at a CAGR of 14.5%. The rise in the number of cancer cases across the globe is likely to contribute to the growth of the cancer vaccines market during the forecast period. For instance, in January 2022, according to the American Cancer Society, there will likely be 1.9 million new cancer diagnoses and 609,360 cancer-related deaths in the US, or roughly 1,670 fatalities every day. The four most common types of cancer worldwide are lung, prostate, bowel, and female breast cancer, accounting for 43 percent of all new cancer cases. The four most common types of cancer worldwide are lung, prostate, bowel, and female breast cancer, accounting for 43% of all new cancer cases. Therefore, the rise in cancer incidence rates globally is anticipated to boost demand for the cancer vaccine market over the coming years. Alternative treatment methods and natural remedies are increasingly popular globally, and this is expected to hurt the revenues of cancer vaccine manufacturing companies. Treatments in the fields of homeopathy, Ayurveda, yoga, acupuncture, and sujok therapy are gaining popularity and slowly replacing some traditional hospital practices. For instance, Ayurvedic medicine, an ancient Indian system of medicine, uses a range of techniques and treatments for cancer. According to the World Health Organization (WHO), some nations are still responding to plant-based treatment as their main medicine source, and developing nations are using the benefits of natural compounds for therapeutic purposes, which is affecting cancer vaccine sales. Also, the global homoeopathic product market is projected to reach $18.6 billion by the end of 2027. This trend is expected to continue during the forecast period and limit the demand for cancer vaccines. Companies in the cancer vaccine market are increasingly investing in preventive or prophylactic vaccines for cancer prevention. Prophylactic vaccines are designed to build immunity in a patient. A prophylactic or preventative vaccine involves introducing antigens into a person's body. According to the World Health Organization, cervical cancer was reported as the second-most common cancer in women, with an estimation of 84% of new cases worldwide. So far, there are 3 HPV vaccines currently available for the prophylaxis of cancer. Two of these will protect against both HPV 16 and HPV 18, which cause 70% of cervical cancer, and the third vaccine prevents 3 more oncogenic HPV types, which further cause 20% of cervical cancers. These three vaccines include Gardasil and Gardasil 9 by Merck and Cervarix by GSK. In May 2020, Merck, a US-based pharmaceutical company, acquired Themis Bioscience for an undisclosed amount. The acquisition is expected to complement Merck's capabilities in the development, manufacturing, and distribution of vaccines. Themis Bioscience is a pharmaceutical company that manufactures vaccines and immune-modulatory therapies developed using the measles virus vector platform, originally based on a vector. Major players in the cancer vaccines market are GlaxoSmithKline, Merck, Aduro Biotech, AstraZeneca PLC., Dendreon, Astellas Pharma Inc., Sanofi Pasteur, Sanpower Group, and CSL Limited. North America was the largest region in the cancer vaccines market in 2022. The regions covered in the global cancer vaccines market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the cancer vaccines market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The cancer vaccines market consists of sales of Bacillus calmette-guérin, Sipuleucel-T, and Human Papillomavirus (HPV) vaccines. Values in this market are "factory gate values," that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organisations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products. The global cancer vaccines market is segmented - 1) By Type: Preventive Cancer Vaccines, Therapeutic Cancer Vaccines 2) By Technology: Dendritic Cells (DC) Cancer Vaccines, Recombinant Cancer Vaccines, Antigen/Adjuvant Cancer Vaccines, Whole Cell Cancer Vaccines, Viral Vector & DNA Cancer Vaccines 3) By Cancer Type: Prostate, Cervical, Colorectal, Throat, Other Cancer Types 4) By End-User: Cancer Treatment Centers, Research Institutes